NCT01731041View on ClinicalTrials.gov

Impact of Ticagrelor Re-load on Pharmacodynamic Profiles

NACompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2014

Study Completion Date

June 30, 2014

Conditions
Coronary Artery Disease
Interventions
DRUG

Ticagrelor 180mg

Patients will receive 180 mg of ticagrelor

DRUG

Ticagrelor 90mg

Patients will receive 90 mg of ticagrelor

Trial Locations (1)

32209

University of Florida, Jacksonville

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Florida

OTHER